Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock
28 mars 2017 16h01 HE
|
Heat Biologics
DURHAM, N.C., March 28, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock
23 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 23, 2017 (GLOBE NEWSWIRE) -- HEAT BIOLOGICS, INC. (“HEAT”) (NASDAQ:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Proposed Public Offering of Common Stock
22 mars 2017 16h03 HE
|
Heat Biologics
DURHAM, N.C., March 22, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
21 mars 2017 07h00 HE
|
Heat Biologics
ELISPOT results suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients Tumor reduction corresponds to enhanced immune...
Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
16 mars 2017 07h02 HE
|
Heat Biologics
Grant to fund Dr. Natasa Strbo’s Zika preclinical research at the University of Miami DURHAM, N.C., March 16, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
13 mars 2017 07h00 HE
|
Heat Biologics
Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) Signs of synergistic efficacy with nivolumab enables expansion to...
Heat Biologics to Present at 29th Annual ROTH Conference
09 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Agreement to Acquire Pelican Therapeutics
08 mars 2017 07h00 HE
|
Heat Biologics
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial DURHAM, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
02 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
17 févr. 2017 07h00 HE
|
Heat Biologics
DURHAM, N.C., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), announced that it presented a poster of its immunological data from its 94-patient Phase 2 trial...